tag:blogger.com,1999:blog-6107187057888804610.post3599931730593558447..comments2024-03-27T05:57:32.259-07:00Comments on IP Komodo: India and pharma compulsory licensingKomodo Dragonhttp://www.blogger.com/profile/02521012324286114258noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-6107187057888804610.post-63595284802860645362012-03-14T05:15:53.503-07:002012-03-14T05:15:53.503-07:00STOP PRESS IP Komodo has been advised of two other...STOP PRESS IP Komodo has been advised of two other SE Asia compulsory licenses granted:<br /><br />On October 5 2004, the Indonesian Government issued a compulsory licence for the manufacture of generic versions of lamivudine and nevirapine, until the end of the patent term in 2011 and 2012 respectively. The licence is for government use, and includes a royalty rate of 0.5% of the net selling value.<br /><br />On September 29 2004, the Malaysian Minister of Domestic Trade and Consumer Affairs issued a two year Goverment use compulsory licence to import from India didanosine (ddI), zidovudine (AZT) and Lamivudine & zidovidine (Combivir).Komodo Dragonhttps://www.blogger.com/profile/02521012324286114258noreply@blogger.com